We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Asuragen Enters Oncology Collaboration with Merck to Develop Pharmacogenomic Tests
News

Asuragen Enters Oncology Collaboration with Merck to Develop Pharmacogenomic Tests

Asuragen Enters Oncology Collaboration with Merck to Develop Pharmacogenomic Tests
News

Asuragen Enters Oncology Collaboration with Merck to Develop Pharmacogenomic Tests

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Asuragen Enters Oncology Collaboration with Merck to Develop Pharmacogenomic Tests"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Asuragen Pharmacogenomic Services, a division of Asuragen, Inc. has entered into research collaboration with Merck & Co., Inc. to develop a biomarker and pharmacogenomic test for cancer clinical trials.

Under the terms of the agreement, Asuragen will apply the information gained from an expression signature identified by Merck’s oncology research program to the development of a diagnostic assay for use in Merck’s cancer clinical trials and to potentially form the basis for commercial companion diagnostic tests for oncology therapies.

Asuragen will receive an undisclosed payment for the development of the test, which is expected to be completed in 2008. Upon completion of assay development and validation, Asuragen will be eligible for additional payments associated with successful transfer of the diagnostic assays to clinical reference laboratories.

“Asuragen’s business model of providing GLP molecular biology services, CLIA testing capabilities, and GMP diagnostic assay development and manufacture is uniquely suited to collaborate with pharmaceutical partners in the clinical validation of drugs in development and the potential future companion diagnostic tests,” said Matt Winkler, Ph.D., CEO/CSO of Asuragen.

“The collaboration with Merck is strong validation of Asuragen’s services capabilities and diagnostic assay development expertise and could lead to diagnostic tests that predict appropriate and improved therapies for the treatment of cancer.”

Advertisement